Skip to main content
Top
Published in: Heart and Vessels 1/2020

01-01-2020 | Cardiomyopathy | Original Article

Elevated lymphatic vessel density measured by Lyve-1 expression in areas of replacement fibrosis in the ventricular septum of patients with hypertrophic obstructive cardiomyopathy (HOCM)

Authors: Xiaowei Jiang, Jingang Cui, Chengzhi Yang, Yunhu Song, Jiansong Yuan, Shengwen Liu, Fenghuan Hu, Weixian Yang, Shubin Qiao

Published in: Heart and Vessels | Issue 1/2020

Login to get access

Abstract

Lymphatic microvessel density (LMVD) contributes to fibrosis in patients with myocardial infarction. However, the role of LMVD in the process of myocardial fibrosis in hypertrophic obstructive cardiomyopathy (HOCM) patients is unclear. We studied LMVD in ventricular septal (VS) samples from 52 individuals (42 was HOCM patients who underwent a transaortic extended septal myectomy, and 10 traffic accident victims), and examined the relationships between the LMVD stained immunohistochemically with lymphatic vessel endothelial hyaluronan receptor (LYVE-1) antibodies, collagen volume fraction (CVF), and clinical characteristics. Compared with traffic accident victims, LMVD was significantly increased in VS of HOCM patients (132.0 ± 49.0 VS 57.8 ± 48.8/mm2, p = 0.000). HOCM patients with syncope had higher level of LMVD than without syncope [166.7 (131.0–201.1) VS 116.4 (80.7–152.1)/mm2, p = 0.017], and LMVD were positively correlated with Log (CVF) (r = 0.431, p = 0.004). On multiple variables regression analysis, LMVD was independently associated with Log (CVF) (r = 0.379, p = 0.009) and syncope (r = 0.335, p = 0.020). In conclusions, the LYVE-1-positive lymphatics have close associations with VS fibrosis in HOCM patients.
Literature
1.
go back to reference Ho CY, Lopez B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R, Gonzalez A, Colan SD, Seidman JG, Diez J, Seidman CE (2010) Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 363:552–563CrossRef Ho CY, Lopez B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R, Gonzalez A, Colan SD, Seidman JG, Diez J, Seidman CE (2010) Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 363:552–563CrossRef
2.
go back to reference Steggerda RC, Damman K, Balt JC, Liebregts M, Ten BJ, van den Berg MP (2014) Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience. JACC Cardiovasc Interv 7:1227–1234CrossRef Steggerda RC, Damman K, Balt JC, Liebregts M, Ten BJ, van den Berg MP (2014) Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience. JACC Cardiovasc Interv 7:1227–1234CrossRef
3.
go back to reference Maron BJ, Maron MS (2013) Hypertrophic cardiomyopathy. Lancet 381:242–255CrossRef Maron BJ, Maron MS (2013) Hypertrophic cardiomyopathy. Lancet 381:242–255CrossRef
4.
go back to reference Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS (2014) Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 64:83–99CrossRef Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS (2014) Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 64:83–99CrossRef
5.
go back to reference O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, Prasad SK (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56:867–874CrossRef O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, Prasad SK (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56:867–874CrossRef
6.
go back to reference Azevedo CF, Nigri M, Higuchi ML, Pomerantzeff PM, Spina GS, Sampaio RO, Tarasoutchi F, Grinberg M, Rochitte CE (2010) Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol 56:278–287CrossRef Azevedo CF, Nigri M, Higuchi ML, Pomerantzeff PM, Spina GS, Sampaio RO, Tarasoutchi F, Grinberg M, Rochitte CE (2010) Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol 56:278–287CrossRef
7.
go back to reference Miller AJ (2011) The grossly invisible and generally ignored lymphatics of the mammalian heart. Med Hypotheses 76:604–606CrossRef Miller AJ (2011) The grossly invisible and generally ignored lymphatics of the mammalian heart. Med Hypotheses 76:604–606CrossRef
8.
go back to reference Cui Y (2010) The role of lymphatic vessels in the heart. Pathophysiology 17:307–314CrossRef Cui Y (2010) The role of lymphatic vessels in the heart. Pathophysiology 17:307–314CrossRef
9.
go back to reference Ludwig LL, Schertel ER, Pratt JW, McClure DE, Ying AJ, Heck CF, Myerowitz PD (1997) Impairment of left ventricular function by acute cardiac lymphatic obstruction. Cardiovasc Res 33:164–171CrossRef Ludwig LL, Schertel ER, Pratt JW, McClure DE, Ying AJ, Heck CF, Myerowitz PD (1997) Impairment of left ventricular function by acute cardiac lymphatic obstruction. Cardiovasc Res 33:164–171CrossRef
10.
go back to reference Dashkevich A, Bloch W, Antonyan A, Fries JU, Geissler HJ (2009) Morphological and quantitative changes of the initial myocardial lymphatics in terminal heart failure. Lymphat Res Biol 7:21–27CrossRef Dashkevich A, Bloch W, Antonyan A, Fries JU, Geissler HJ (2009) Morphological and quantitative changes of the initial myocardial lymphatics in terminal heart failure. Lymphat Res Biol 7:21–27CrossRef
11.
go back to reference Kholova I, Dragneva G, Cermakova P, Laidinen S, Kaskenpaa N, Hazes T, Cermakova E, Steiner I, Yla-Herttuala S (2011) Lymphatic vasculature is increased in heart valves, ischaemic and inflamed hearts and in cholesterol-rich and calcified atherosclerotic lesions. Eur J Clin Invest 41:487–497CrossRef Kholova I, Dragneva G, Cermakova P, Laidinen S, Kaskenpaa N, Hazes T, Cermakova E, Steiner I, Yla-Herttuala S (2011) Lymphatic vasculature is increased in heart valves, ischaemic and inflamed hearts and in cholesterol-rich and calcified atherosclerotic lesions. Eur J Clin Invest 41:487–497CrossRef
12.
go back to reference Henri O, Pouehe C, Houssari M, Galas L, Nicol L, Edwards-Levy F, Henry JP, Dumesnil A, Boukhalfa I, Banquet S, Schapman D, Thuillez C, Richard V, Mulder P, Brakenhielm E (2016) Selective stimulation of cardiac lymphangiogenesis reduces myocardial edema and fibrosis leading to improved cardiac function following myocardial infarction. Circulation 133(1484–1497):1497 Henri O, Pouehe C, Houssari M, Galas L, Nicol L, Edwards-Levy F, Henry JP, Dumesnil A, Boukhalfa I, Banquet S, Schapman D, Thuillez C, Richard V, Mulder P, Brakenhielm E (2016) Selective stimulation of cardiac lymphangiogenesis reduces myocardial edema and fibrosis leading to improved cardiac function following myocardial infarction. Circulation 133(1484–1497):1497
13.
go back to reference Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the european society of cardiology (ESC). Eur Heart J 35:2733–2779CrossRef Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the european society of cardiology (ESC). Eur Heart J 35:2733–2779CrossRef
14.
go back to reference Nagueh SF, Bierig SM, Budoff MJ, Desai M, Dilsizian V, Eidem B, Goldstein SA, Hung J, Maron MS, Ommen SR, Woo A (2011) American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr 24:473–498CrossRef Nagueh SF, Bierig SM, Budoff MJ, Desai M, Dilsizian V, Eidem B, Goldstein SA, Hung J, Maron MS, Ommen SR, Woo A (2011) American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr 24:473–498CrossRef
15.
go back to reference Liu Y, Song Y, Gao G, Ran J, Su W, Li H, Tang Y, Duan F, Sun H (2016) Outcomes of an extended Morrow procedure without a concomitant mitral valve procedure for hypertrophic obstructive cardiomyopathy. Sci Rep 6:29031CrossRef Liu Y, Song Y, Gao G, Ran J, Su W, Li H, Tang Y, Duan F, Sun H (2016) Outcomes of an extended Morrow procedure without a concomitant mitral valve procedure for hypertrophic obstructive cardiomyopathy. Sci Rep 6:29031CrossRef
16.
go back to reference Vuorio T, Tirronen A, Yla-Herttuala S (2017) Cardiac Lymphatics—a new avenue for therapeutics? Trends Endocrinol Metab 28:285–296CrossRef Vuorio T, Tirronen A, Yla-Herttuala S (2017) Cardiac Lymphatics—a new avenue for therapeutics? Trends Endocrinol Metab 28:285–296CrossRef
17.
go back to reference Vieira JM, Norman S, Villa DCC, Cahill TJ, Barnette DN, Gunadasa-Rohling M, Johnson LA, Greaves DR, Carr CA, Jackson DG, Riley PR (2018) The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction. J Clin Invest 128:3402–3412CrossRef Vieira JM, Norman S, Villa DCC, Cahill TJ, Barnette DN, Gunadasa-Rohling M, Johnson LA, Greaves DR, Carr CA, Jackson DG, Riley PR (2018) The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction. J Clin Invest 128:3402–3412CrossRef
18.
go back to reference Dieterich LC, Seidel CD, Detmar M (2014) Lymphatic vessels: new targets for the treatment of inflammatory diseases. Angiogenesis 17:359–371CrossRef Dieterich LC, Seidel CD, Detmar M (2014) Lymphatic vessels: new targets for the treatment of inflammatory diseases. Angiogenesis 17:359–371CrossRef
19.
go back to reference Oliver G (2004) Lymphatic vasculature development. Nat Rev Immunol 4:35–45CrossRef Oliver G (2004) Lymphatic vasculature development. Nat Rev Immunol 4:35–45CrossRef
Metadata
Title
Elevated lymphatic vessel density measured by Lyve-1 expression in areas of replacement fibrosis in the ventricular septum of patients with hypertrophic obstructive cardiomyopathy (HOCM)
Authors
Xiaowei Jiang
Jingang Cui
Chengzhi Yang
Yunhu Song
Jiansong Yuan
Shengwen Liu
Fenghuan Hu
Weixian Yang
Shubin Qiao
Publication date
01-01-2020
Publisher
Springer Japan
Keyword
Cardiomyopathy
Published in
Heart and Vessels / Issue 1/2020
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-019-01463-5

Other articles of this Issue 1/2020

Heart and Vessels 1/2020 Go to the issue